Skip to main content
. 2015 Jan 29;10:211–221. doi: 10.2147/COPD.S76061

Table S2.

Physiological and inflammatory measures

Mean (SD) unless otherwise specified n=active treatment: placebo Active treatment (simvastatin) group
Placebo group
Mean difference Δ active treatment versus Δ placebo (CI) P-value (between arm change)
Pre-treatment Post-treatment Post–Pre mean Δ Pre-treatment Post-treatment Post-Pre mean Δ
Circulating MMP-9 (ng/mL) 53.1 (16.3) 50.4 (16.8) −2.9 60.4 (17.2) 56.1 (17.8) −3.1 0.2 (–10.8, 11.2) 0.97
Circulating hs-CRP (mg/L) n=31:32* 3.5 (3.1) 2.9 (3.9) 0.8 3.0 (3.0) 3.0 (2.9) 0.2 0.5 (–3.2, 4.1) 0.79
Dominant hand grip strength (kg) n=31:33 35.3 (9.2) 35.3 (8.5) 0.1 32.2 (8.3) 33.0 (8.4) 0.9 −0.8 (–2.6, 0.9) 0.36
6MWD (m) n=30:31 343 (75) 339 (84) −3.6 332 (76) 338 (88) 5.1 −8.7 (–23.6, 6.2) 0.25
FEV1 (L) n=31:33 1.59 (0.6) 1.59 (0.6) 0.0 1.41 (0.5) 1.43 (0.6) 0.0 0 (–0.07, 0.05) 0.77
FVC (L) n=31:33 3.40 (0.9) 3.3 (0.9) −0.1 3.06 (1.0) 3.07 (1.0) 0.0 −0.1 (–0.2, 0.02) 0.09
Sputum neutrophils (%) n=8:12* 75.2 (1.5) 75.3 (1.4) −1.9 77.5 (1.3) 61.4 (2.2) −6.3 4.4 (–12.0, 20.8) 0.58
Actual sputum neutrophils n=8:12* 306 (2) 310 (1) −2.8 314 (1.2) 246 (2) −27.8 25.0 (–50.1, 101.0) 0.50
FeNO 50 mL (ppm) n=17:19* 23.6 (1.9) 21.8 (1.9) −2.2 14.5 (1.9) 17.8 (2.1) 6.1 −8.2 (–19.1, 2.6) 0.13
FeNO intercept n=16:19* 34.4 (2.5) 36.9 (2.5) −0.1 27.7 (2.1) 31.1 (2.2) 4.4 −4.5 (–25.3, 16.4) 0.67
FeNO gradient n=16:19* 8.9 (2.5) 8.1 (2.5) −2.0 4.8 (2.1) 5.9 (3.2) 3.8 −5.9 (–13.5, 1.7) 0.13

Notes:

*

Geometric mean.

Abbreviations: FEV1, forced expired volume in one second; FVC, forced vital capacity; FeNO, fraction of expired nitric oxide; L, litre; MMP-9, matrix metalloprotease-9; hs-CRP, high sensitivity C-reactive protein; 6MWD, six-minute walking distance; SD, standard deviation; CI, confidence interval.